Targeting cld18.2 positive patients with new cancer drug, TORL-2-307-ADC in patients with advanced cancer. This is a phase 1 study and UCLA Dr. Zev Wainberg, Santa Monica is conducting this research study. It's a 2 part study with part 1 it's given as a single agent. In part 2, the MTD (maximum tolerated dose) will be determined. It's for those with advanced gastric or gastroesophageal cancer. 30 participants in phase 1 and up to 80 in phase 2.
They are recruiting now so if interested give dr Wainberg a call. Please post if you decide to try this trial and wishing the best for you. I'll post if I find a clinical trial that I qualify for.